Duke University and PAVmed Partner on Oesophageal Imaging Technology

PAVmed has signed a non-binding letter of intent (LoI) with Duke University to license a novel oesophageal imaging platform that could transform endoscopic cancer detection. The technology combines angle-resolved low coherence interferometry (a/LCI) with optical coherence tomography (OCT)**, offering a less invasive alternative to biopsies in identifying precancerous changes.

Developed by Duke’s Dr. Adam Wax in collaboration with Dr. Nicholas Shaheen of UNC, early studies showed a/LCI could detect oesophageal precancer with 100% sensitivity and 88% accuracy. A pilot trial integrating OCT improved specificity in detecting dysplasia during surveillance and pre-treatment, with results under peer review.

Under the LoI, a newly formed PAVmed subsidiary aims to secure exclusive global licensing rights. The company’s Lucid Diagnostics unit already markets EsoGuard and EsoCheck for oesophageal precancer screening. If finalized, the agreement could expand PAVmed’s diagnostic portfolio, enabling more precise, biopsy-free evaluation and treatment of high-risk patients.

28-08-2025